title: A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
abstract: OBJECTIVE
  Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings.
  
  
  METHODS
  Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function were eligible. Patients were treated with carboplatin AUC 5 intravenously over 30-60 minutes on day 1, followed by CPT-11(irinotecan) 50 mg/m(2) intravenously over 30-90 minutes on days 1 and 8 every 3 weeks for 4-6 cycles at the discretion of the treating physician.
  
  
  RESULTS
  Fifty-six patients were enrolled, and 50 patients were eligible. The median age of patients was 60.1 years. The most common toxicities were neutropenia, thrombocytopenia, nausea/vomiting, and dehydration. The overall response rate was 58%. Median PFS was 5.3 months, median overall survival was 9.7 months, and 1-year overall survival was 28.7%.
  
  
  CONCLUSIONS
  Carboplatin and irinotecan is a safe and reasonable combination for the treatment of patients with ED-SCLC.
authors.affiliation: Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
authors.forename: Leora
authors.initials: L
authors.lastname: Horn
authors.forename: Zhiguo
authors.initials: Z
authors.lastname: Zhao
authors.forename: Alan
authors.initials: A
authors.lastname: Sandler
authors.forename: David
authors.initials: D
authors.lastname: Johnson
authors.forename: Yu
authors.initials: Y
authors.lastname: Shyr
authors.forename: Steven
authors.initials: S
authors.lastname: Wolff
authors.forename: Russell F
authors.initials: RF
authors.lastname: Devore
authors.forename: Janessa
authors.initials: J
authors.lastname: Laskin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000077146:Irinotecan; D016190:Carboplatin; D002166:Camptothecin